The short version
"Are compounded peptides legal under the FDA?" is one of the most-asked peptide questions on the internet, and the honest answer is: it depends — on the specific peptide, the specific pharmacy, and the specific prescription. The category as a whole is neither legal nor illegal. The framework is per-substance.
Compounded medications, including compounded peptides, are governed by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. 503A applies to traditional pharmacy compounding for an individual patient under prescription; 503B applies to outsourcing facilities producing larger batches for use by healthcare facilities. Both have their own rules about what may be compounded and from what source materials.
| Question | Answer |
|---|---|
| Are compounded peptides categorically legal? | No — depends on the specific substance |
| Are compounded peptides categorically illegal? | No — many are routinely compounded under 503A |
| Does FDA approve compounded products? | No — FDA approves drugs, not compounded preparations |
| Is a prescription required? | Yes — 503A compounding is patient-specific by definition |
| Is buying "research-only" peptides legal? | Not a medical pathway; outside the FDA framework |
Section 503A and 503B
Section 503A allows a state-licensed pharmacy or physician to compound a medication for an individual patient pursuant to a valid prescription, using bulk drug substances that meet specific eligibility criteria. The substance must either be (a) the active ingredient of an FDA-approved drug, (b) appear on a USP or National Formulary monograph, or (c) appear on FDA's "503A bulks list."
Section 503B applies to "outsourcing facilities" that compound at larger scale, often for healthcare facility use. 503B has its own bulks list. The two regimes are related but distinct, and most peptide telehealth runs through 503A pharmacies.
"Are compounded peptides legal" is the wrong frame. The right frame is: which peptide, from which pharmacy, on whose prescription.
Category 1 vs. Category 2
FDA evaluates nominated bulk substances and assigns them to Category 1 or Category 2 of its 503A evaluation. Category 1 substances are permitted for compounding pending final rulemaking — the substance has not raised significant safety concerns. Category 2 substances have been flagged with significant safety concerns; FDA has indicated they should not be used for compounding under 503A while concerns are unresolved.
BPC-157 and TB-500 (thymosin beta-4 fragment) were placed in Category 2 in 2023. Sermorelin and several other peptide secretagogues sit in a more permissive position, with their precise status varying year to year. The list is dynamic, and reputable 503A pharmacies track it closely.
What this means in practice
For a patient, the practical effect of all of this: a peptide compound from a 503A pharmacy on a valid prescription, where the bulk substance has a clear path under federal compounding rules, is the legitimate framework. A peptide bought from a "research chemical" website, or a foreign mail-order vendor, or a domestic gray-market reseller, is operating outside that framework — regardless of the marketing language used.
For more on what to look for in a provider, see the provider comparison checklist. For more on sourcing and the difference between legitimate and gray-market pathways, see the sourcing and ordering guide. For state-by-state context, see peptides legal by state, 2026.
Questions worth asking your provider
- What is the current FDA bulk-substance category of the peptide you'd be prescribing?
- Is the pharmacy a 503A or 503B facility, and what is its licensure footprint?
- Is the prescriber licensed in my state?
- What is the source of the bulk substance the pharmacy compounds from?
- How does the platform handle peptides that move from Category 1 to Category 2 mid-year?
Sources